In fiscal year 2025, LigaChem Biosciences (141080) reported revenue of 141.6 billion KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|---|---|---|---|
| 2025 | 141.6 billion KRW | -106.5 billion KRW | -91.6 billion KRW | [source] |
| 2024 | 125.9 billion KRW | -20.9 billion KRW | 7.8 billion KRW | [source] |
| 2023 | 34.1 billion KRW | -80.8 billion KRW | -73.7 billion KRW | [source] |
| 2022 | — | -50.4 billion KRW | -45.1 billion KRW | [source] |
| 2021 | — | -27.7 billion KRW | -23.4 billion KRW | [source] |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|---|---|---|---|
| 2025 | 660.7 billion KRW | 83.3 billion KRW | 577.5 billion KRW | [source] |
| 2024 | 743.2 billion KRW | 125.8 billion KRW | 617.4 billion KRW | [source] |
| 2023 | 192.4 billion KRW | 41.7 billion KRW | 150.8 billion KRW | [source] |
| 2022 | 256.2 billion KRW | 32.9 billion KRW | 223.3 billion KRW | [source] |
| 2021 | 293.2 billion KRW | 34.5 billion KRW | 258.8 billion KRW | [source] |
This company has no revenue account in the DART financial statements. Industry-specific accounts such as insurance or interest income are not converted to revenue.